Objectives: The original Pediatric Sepsis Biomarker Risk Model and revised (Pediatric Sepsis Biomarker Risk Model-II) biomarkerbased risk prediction models have demonstrated utility for estimating baseline 28-day mortality risk in pediatric sepsis. Given the paucity of prediction tools in pediatric acute respiratory distress syndrome, and given the overlapping pathophysiology between sepsis and acute respiratory distress syndrome, we tested the utility of Pediatric Sepsis Biomarker Risk Model and Pediatric Sepsis Biomarker Risk Model-II for mortality prediction in a cohort of pediatric acute respiratory distress syndrome, with an a priori plan to revise the model if these existing models performed poorly. Design: Prospective observational cohort study. Setting: University affiliated PICU. Patients: Mechanically ventilated children with acute respiratory distress syndrome. Interventions: Blood collection within 24 hours of acute respiratory distress syndrome onset and biomarker measurements. Measurements and Main Results: In 152 children with acute respiratory distress syndrome, Pediatric Sepsis Biomarker Risk Model performed poorly and Pediatric Sepsis Biomarker Risk Model-II performed modestly (areas under receiver operating characteristic curve of 0.61 and 0.76, respectively). Therefore, we randomly selected 80% of the cohort (n = 122) to rederive a risk prediction model for pediatric acute respiratory distress syndrome. We used classification and regression tree methodology, considering the Pediatric Sepsis Biomarker Risk Model biomarkers in addition to variables relevant to acute respiratory distress syndrome. The final model was comprised of three biomarkers and age, and more accurately estimated baseline mortality risk (area under receiver operating characteristic curve 0.85, p < 0.001 and p = 0.053 compared with Pediatric Sepsis Biomarker Risk Model and Pediatric Sepsis Biomarker Risk Model-II, respectively). The model was tested in the remaining 20% of subjects (n = 30) and demonstrated similar test characteristics. Conclusions: A validated, biomarker-based risk stratification tool designed for pediatric sepsis was adapted for use in pediatric acute respiratory distress syndrome. The newly derived Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model demonstrates good test characteristics internally and requires external validation in a larger cohort. Tools such as Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model have the potential to provide improved risk stratification and prognostic enrichment for future trials in pediatric acute respiratory distress syndrome. (Crit Care Med 2018; 46:e9-e16) Key Words: acute respiratory distress syndrome; biomarker; interleukin-8; mortality; pediatric T he heterogeneity of acute respiratory distress syndrome (ARDS) translates to complex decision-making for both clinicians and researchers. Prognostic enrichment, in which a study population is enriched for subjects more likely to have the primary outcome of interest, may improve future trial selection. Enrichment tools offer the potential for reliable identification of patients most likely to benefit from higher risk or aggressive interventions, as well as stratify risk in trials to assess whether efficacy of an intervention varies with the variable mortality risk of the population. For instance, the ARDS et Curarisation Systematique trial testing cisatracurium (1) and PROne Positioning in SEVere ARDS trial (2) less than 150 (higher risk of death), with positive results. However, oxygenation is inconsistently associated with outcome in ARDS (3), with minimal prognostic utility (4), making it an imperfect stratification tool. For children, this is compounded by the fact that neither the 1994 American-European Consensus Conference (5) nor the 2012 Berlin (4) definitions of ARDS addressed the pediatric population.
T he heterogeneity of acute respiratory distress syndrome (ARDS) translates to complex decision-making for both clinicians and researchers. Prognostic enrichment, in which a study population is enriched for subjects more likely to have the primary outcome of interest, may improve future trial selection. Enrichment tools offer the potential for reliable identification of patients most likely to benefit from higher risk or aggressive interventions, as well as stratify risk in trials to assess whether efficacy of an intervention varies with the variable mortality risk of the population. For instance, the ARDS et Curarisation Systematique trial testing cisatracurium (1) and PROne Positioning in SEVere ARDS trial (2) used prognostic enrichment by limiting enrollment to patients with Pao 2 /Fio 2 less than 150 (higher risk of death), with positive results. However, oxygenation is inconsistently associated with outcome in ARDS (3), with minimal prognostic utility (4), making it an imperfect stratification tool. For children, this is compounded by the fact that neither the 1994 American-European Consensus Conference (5) nor the 2012 Berlin (4) definitions of ARDS addressed the pediatric population.
The Pediatric Sepsis Biomarker Risk Model (PERSEVERE) has demonstrated utility for estimating baseline 28-day mortality risk in septic shock (6, 7) . PERSEVERE was developed using transcriptomics and quantification of circulating proteins, resulting in a classification and regression tree (CART)-based model incorporating five biomarkers plus age. Testing within multisystem organ failure (MSOF) phenotypes prompted a revised model (PERSEVERE-II) incorporating platelet levels (8) . Given the overlapping pathophysiology of sepsis and ARDS (9, 10) , and since infection accounts for most pediatric ARDS triggers (11) (12) (13) , we tested the utility of PERSEVERE and PERSEVERE-II for mortality prediction in a cohort of pediatric ARDS, with an a priori plan to revise the model if these existing models performed poorly.
METHODS

Study Design and Patient Selection
This ongoing prospective cohort study was approved by the Children's Hospital of Philadelphia's (CHOP) Institutional Review Board, and informed consent was obtained from caregivers prior to enrollment. Clinical data were collected prospectively. Consecutive patients in the PICU were screened for Berlin-defined ARDS between July 1, 2014, and December 30, 2016. Inclusion criteria were 1) acute (≤ 7 d of known risk factor) respiratory failure requiring invasive (endotracheal) mechanical ventilation, 2) invasive arterial access, 3) age greater than 1 month (to avoid confounding by neonatal physiology) and less than 18 years, 4) Pao 2 /Fio 2 less than or equal to 300 on two consecutive arterial blood gases separated by greater than or equal to 1 hour on positive end-expiratory pressure (PEEP) greater than or equal to 5 cm H 2 O, and 5) bilateral infiltrates on radiograph. Exclusion criteria were 1) respiratory failure from cardiac failure (by echocardiography), 2) exacerbation of underlying chronic lung disease, 3) chronic ventilator dependence, 4) cyanotic heart disease, 5) ventilation for greater than 7 days before Pao 2 /Fio 2 less than or equal to 300, 6) ARDS established outside of the CHOP PICU, 7) inability to obtain consent, or 8) prior enrollment.
Absent a standardized ventilator protocol, institutional practice is to initiate conventional ventilation with PEEP greater than or equal to 5 cm H 2 O and attempt to wean Fio 2 to less than or equal to 0.60, keeping Pao 2 greater than or equal to 60 mm Hg. Inability to wean Fio 2 prompts PEEP escalation and subsequent efforts to wean Fio 2 . We exclusively use decelerating flow (either pressure control or pressure-regulated volume control). Persistently elevated peak pressures (≥ 35 cm H 2 O), hypercarbia (Paco 2 ≥ 80), or oxygenation difficulties (inability to wean Fio 2 ≤ 0.60 despite increasing PEEP) prompted consideration for changing mode of ventilation or escalating to extracorporeal support. Actual transition was left to the discretion of the attending physician. There was no standardization of ancillary therapies (inhaled nitric oxide, neuromuscular blockade, and corticosteroids). 
Plasma Collection and Measurements
PERSEVERE Biomarkers
PERSEVERE includes C-C chemokine ligand 3 (CCL3), interleukin 8 (IL8), heat shock protein 70 kda 1B (HSPA1B), granzyme B, and matrix metallopeptidase 8 (MMP8) (6) . Biomarker concentrations were measured using a multiplex magnetic bead platform (MILLIPLEX MAP) designed for PERSEVERE by EMD Millipore (Billerica, MA), and a Luminex 100/200 system (Luminex, Austin, TX), according to manufacturers' specifications. Assay performance data have been previously published (6) . Platelets measured at the time of blood collection for biomarkers were included for modeling of PERSEVERE-II (8).
Equations and Definitions
Oxygenation was measured using Pao 2 /Fio 2 and oxygenation index (OI, [mean airway pressure × Fio 2 × 100]/ Pao 2 ). The vasopressor score (14) was dopamine (µg/kg/min) × 1 + dobutamine (µg/kg/min) × 1 + epinephrine (µg/kg/min) × 100 + norepinephrine (µg/kg/min) × 100 + phenylephrine (µg/kg/min) × 100 + milrinone (µg/kg/min) × 10 + vasopressin (U/kg/min) × 10,000. Severity of illness was scored using the Pediatric Risk of Mortality (PRISM) III at 12 hours. Nonpulmonary organ failures at ARDS diagnosis were identified using accepted pediatric definitions (15) . The designation of "immunocompromised" required presence of an immunocompromising diagnosis (oncologic, immunologic, rheumatologic, transplant) and active immunosuppressive therapy, or congenital immunodeficiency (16) . Etiology of ARDS was dichotomized to "infectious" or "noninfectious." The primary outcome was PICU mortality. We also report ventilator-free days (VFDs) at 28 days, defined by subtracting total ventilator days from 28 in survivors. All patients with ventilator days greater than or equal to 28 days and all PICU nonsurvivors were assigned VFD equals to 0.
CART and Other Statistical Analyses
Data are reported as median (interquartile range [IQR] ) and differences between groups compared using Wilcoxon ranksum test. Categorical data were compared using Fisher exact test. Descriptive analyses were performed with Stata/SE 14.2 (StataCorp, College Station, TX).
Initially, subjects were classified according to PERSEVERE and PERSEVERE-II and assigned a baseline probability of Critical Care Medicine www.ccmjournal.org e11 mortality. Performance was assessed using diagnostic test statistics, including computing area under the receiver operating characteristic (AUROC) curve. A priori, we determined that if PERSEVERE and PERSEVERE-II did not perform well in this cohort, we would rederive an ARDS-specific model using the PERSEVERE biomarkers in addition to variables relevant to ARDS. Additional variables considered for the Pediatric ARDS Biomarker Risk Model (PARDSEVERE) included age, platelets, infectious versus noninfectious ARDS etiology, presence or absence of an immunocompromising condition, and initial and 24-hour Pao 2 /Fio 2 and OI. Age and platelets were modeled because they were part of PERSEVERE and PERSEVERE-II, respectively; infectious ARDS etiology was modeled because PERSEVERE was developed in a septic cohort, and we reasoned this may affect model performance; immunocompromised status is a known strong baseline predictor of mortality in pediatric ARDS (13, (17) (18) (19) ; oxygenation at onset and 24 hours was modeled to account for accurate stratification for ARDS severity (13) . We used CART methodology (Salford Predictive Modeler v8.0; Salford Systems, San Diego, CA). Terminal nodes that did not improve classification based on the class probability method were pruned. Weighting of cases and costs for misclassification were not used. The PARDSEVERE model was developed in a random 80% sampling of the ARDS cohort and tested in the remaining 20%. Diagnostic statistics were computed separately for derivation and test cohorts. Additionally, we tested if VFD decreased across worsening PARDSEVERE categories using nonparametric test of trend. Finally, to assess impact on duration of ventilation, Fine and Gray competing risk regression (20) was used to test association of PARDSEVERE risk categories with probability of extubation, with extubation as primary outcome and death as competing risk.
RESULTS
Description of the Cohort
Over the study period, 152 children with ARDS were included, with biomarkers measured at median 11 hours (IQR, 6-19 hr) after ARDS onset. Subjects were intubated for a median of 4 hours (0-10 hr) prior to meeting ARDS criteria. Demographics are provided in Table 1 . The 24 nonsurvivors (16%) had worse PRISM III scores, more organ failures, higher vasopressor scores, and were more likely to be immunocompromised.
Of the 24 deaths, 12 had an infectious ARDS etiology (six pneumonia, six nonpulmonary sepsis), and 12 had noninfectious (six aspiration, four drowning, one smoke inhalation, one trauma). Twelve patients died after withdrawal for poor neurologic prognosis, nine of MSOF, and three of refractory hypoxemia.
Utility of PERSEVERE and PERSEVERE-II in Pediatric ARDS
We initially applied the PERSEVERE predictive model to the ARDS cohort (Supplementary Fig. 1 
Development of PARDSEVERE
Because of the modest predictive ability of PERSEVERE-II, we developed a mortality prediction model specifically for the ARDS cohort, using the PERSEVERE biomarkers and additional variables as described in Methods. The final PARDSE-VERE model retained CCL3, HSPA1B, IL8, and age (Fig. 1) . In the derivation cohort, terminal nodes 1 and 4 were low risk, with mortality rates of 0%. Terminal node 2 was intermediate risk, with 20% mortality. Terminal nodes 3 and 5 were high risk, with mortality rates greater than 33%. Discriminative ability was good for the derivation, with AUROC of 0.85 ( Table 2 ). The test cohort displayed similar characteristics (Fig. 2) , with low-risk node mortality of 0% and 5.6%, the intermediate node with 20% mortality, and high-risk node mortality of greater than 33%. PARDSEVERE demonstrated improved mortality discrimination over PERSEVERE (p < 0.001) and PERSEVERE-II (p = 0.053) when comparing the respective AUROC. PARDSEVERE performed comparably to PRISM III (AUROC, 0.80; 95% CI, 0.60-0.91) and number of nonpulmonary organ failures (AUROC, 0.85; 95% CI, 0.73-0.92; both p > 0.05 relative to PARDSEVERE). When restricted to immunocompetent patients, PARDSEVERE also demonstrated excellent discrimination (n = 124; AUROC, 0.89; 95% CI, 0.83-0.94). Finally, worsening PARDSEVERE risk categories demonstrated decreasing VFD and decreased probability of extubation given the competing risk of death (Supplementary Fig. 3 , Supplemental Digital Content 4, http://links.lww. com/CCM/C903; legend, Supplemental Digital Content 6, http://links.lww.com/CCM/C905).
Biological plausibility of the model was demonstrated by examination of false positives (i.e., those predicted to die by PARDSEVERE but survived). False positives were more ill than true negatives (Table 3) , with higher PRISM III, more nonpulmonary organ failures, higher vasopressor scores, and higher proportion of immunocompromised. This suggests that the biomarker-based PARDSEVERE accurately identified increasing illness severity, and that false positives were at higher risk of death, which was potentially mitigated by clinical management.
DISCUSSION
PERSEVERE and PERSEVERE-II, risk prediction tools developed for pediatric sepsis, did not perform well in pediatric ARDS. Therefore, we derived PARDSEVERE using the PERSE-VERE biomarkers, in addition to select clinical variables, using CART methodology, similar to development of PERSEVERE. PARDSEVERE demonstrated good test characteristics within the derivation and test subsets sampled from the entire ARDS cohort and suggested biological plausibility, with higher severity of illness in false positives (predicted to die) relative to true negatives. PARDSEVERE separated the cohort into low-, intermediate-, and high-probability of death and may have utility for risk stratification or prognostic enrichment in future pediatric ARDS trials.
The biomarkers CCL3, HSPA1B, and IL8 were retained in the PARDSEVERE predictive model. These biomarkers constitute the primary predictors in PERSEVERE for pediatric sepsis (6) . IL8 is associated with increased mortality in both pediatric and adult sepsis and ARDS (21) (22) (23) (24) (25) . Half of the deaths in this cohort were noninfectious, and the retention of these three biomarkers in a mortality prediction model suggests that sepsis shares a circulating cytokine profile with other inflammatory conditions (ARDS in this study), some of which are typically considered sterile. This raises the intriguing possibility of testing these three biomarkers for stratifying mortality risk in noninfectious (yet inflammatory) etiologies, such as trauma, cardiac arrest, and postcardiopulmonary bypass. This is especially true if the shared mortality risk from these conditions is predominantly manifested through MSOF, with which these biomarkers appear to be correlated.
It is notable that previously described predictors of mortality, such as immunocompromised status and oxygenation (11, 13, 19, 26) , were not retained in PARDSEVERE. A recently proposed simple model (19) for predicting mortality in pediatric ARDS using only day 1 OI and cancer/stem-cell transplant status resulted in modest predictive ability in our cohort (AUROC, 0.71; 95% CI, 0.60-0.83). PARDSEVERE outperformed this model when comparing AUROC (p = 0.047). One potential explanation is that the mortality risk from being immunocompromised is better explained by circulating biomarkers, rather than a binary clinical designation reflecting immune function. Four of the five PERSEVERE biomarkers (other than MMP8) and platelets were elevated in immunocompromised patients (Supplementary Table 2 , Supplemental Digital Content 5, http://links.lww.com/CCM/ C904). The retention of the biomarkers, but not the clinical condition, suggests that mortality risk was better stratified by the biomarker profile. OI was only associated with a single biomarker (HSPA1B, rho = 0.29; p < 0.001), and the lack of inclusion in PARDSEVERE may be due to the low sample size, infrequency of death, or the over-representation of deaths for neurologic (rather than hypoxemia or MSOF) reasons. Despite these limitations, PARDSEVERE demonstrated biological plausibility, with higher illness severity in false positives relative to true negatives, and retention of the same three biomarkers comprising the upper level decision rules for PERSEVERE. External validation of PARDSEVERE in a larger population will be necessary to determine whether oxygenation would retain predictive utility in the presence of these markers, and as with PERSEVERE, we expect this tool to be updated with additional data.
PARDSEVERE performs comparably to PRISM III and number of nonpulmonary organ failures. A biomarker-based risk stratification tool offers advantages over PRISM III, which is typically neither available nor calculated at presentation. Furthermore, experts in the field have argued strongly against using illness severity scores (such as PRISM) for individual patient stratification, entry criteria for trials, or treatment decisions, as such scores were not designed for use in individual patients or specific interventions (27) . The similar performance of organ failures suggests that PARDSEVERE is reproducing the mortality risk associated with MSOF in this ARDS cohort. PARDSEVERE may offer advantages over an organ failure score in its objectivity and the association of biomarkers with underlying inflammatory pathophysiology, thus potentially identifying targetable pathways. Calfee et al (10) demonstrated the presence of different endotypes of adult ARDS defined by circulating biomarkers; PARDSEVERE may similarly be identifying endotypes of pediatric ARDS with varying degrees of inflammatory insult defined, in part, by the three biomarkers.
Our study has limitations. The study was conducted at a single center, and although demographics and severity are comparable to other cohorts, mortality rate, ventilator practices, and utilization of ancillary therapies or alternative ventilator modes may not allow translation to other institutions. However, a lack of protocolization should improve generalizability. We measured plasma biomarkers, which may not be the compartment most reflective of ARDS biology. However, given the infrequency of bronchoalveolar lavage in our population, it was not feasible to include biomarkers measured from the alveolar space. Patient heterogeneity, low number of total deaths, high proportion of neurologic deaths, and modest proportion of deaths from patients with an infectious etiology limit the model. However, the rarity of deaths in this cohort is typical for modern pediatric ARDS cohorts (13, 19) . Although the etiology of death in pediatric ARDS is unknown, Critical Care Medicine www.ccmjournal.org e15 adult ARDS data suggest that primary neurologic failure is a common phenomenon (28) . In that study, 29% of adult ARDS patients had neurologic dysfunction as the organ failure precipitating death, and 67% had active withdrawal of support. Finally, clinical application of PARDSEVERE requires an efficient platform that can generate actionable data within about 1 hour and is amenable to measuring individual samples. The technologies to achieve these capabilities are available, and a rapid assay platform for the PERSEVERE biomarkers is currently in development.
Despite limitations, PARDSEVERE demonstrated good predictive characteristics, was internally validated, and had biological plausibility. Samples were collected prospectively in a well-characterized, contemporary pediatric ARDS cohort early in the disease course and demonstrated utility for stratifying the outcomes VFD at 28 days and probability of extubation given competing risk of death. The ability to stratify outcomes other than mortality is necessary for pediatric ARDS, as mortality is low and only partly related to severity of lung injury.
CONCLUSIONS
A validated, biomarker-based risk stratification tool designed for pediatric sepsis was adapted for use in pediatric ARDS. The newly derived PARDSEVERE demonstrates good test characteristics internally and requires external validation in a larger cohort. Tools such as PARDSEVERE have the potential to provide improved risk stratification and prognostic enrichment for future trials in pediatric ARDS.
